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Femorofemoral  Crossover Grafts for Claudication: A Safe and 
Reliable Procedure 
M. Berce, R. D. Sayers* and J. H. Millert 
Department of Vascular Surgery, Royal Adelaide Hospital, Adelaide, South Australia 5000 
Objective: To evaluate the role of femorofemoral crossover grafts in patients with disabling claudication. 
Design. Retrospective study. 
Setting: University hospital. 
Materials, Two hundred and eleven patients with iliac artery disease undergoing femorofemoral crossover grafts for 
disabling claudication. 
Chief outcome measures: Perioperative mortality, follow-up cumulative graft patency, limb loss, survival, graft infection 
and false aneurysm formation were evaluated to determine the immediate and long-term outcome of the procedure. 
Main results" Primary and secondary graft patency at 5 years was 72% and 89% respectively: There were no perioperative 
deaths (zero 30 day mortality). Dacron was used in 66 patients (31%) and PTFE in 145 (69%). There were no differences 
in patency between the two graft materials but eight Dacron grafts (12.1%) were removed because of complications (false 
aneurysm or infection) compared to four PTFE grafts (2.7%)(p < 0.00I Chi-square). Five patients (2%) have undergone a 
major lower limb amputation. Forty-one patients (19%) have required subsequent inflow procedures which represents a 
cumulative need for inflow of 5% per year. 
Conclusions: Femorofemoral crossover grafts are a safe and reliable procedure in patients with disabling claudication 
caused by unilateral iliac artery disease. 
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Introduction 
Femorofemoral crossover is an extra-anatomical arte- 
rial bypass which is usually performed in patients 
with ischaemic rest pain or tissue necrosis (ulceration 
and/or gangrene) caused by unilateral iliac artery 
occlusion. In these patients it is an accepted technique 
of limb salvage and avoids a major lower limb 
amputation. In patients with disabling claudication 
caused by iliac artery disease an aortofemoral or 
iliofemoral bypass is preferred by many surgeons 
rather than a femorofemoral crossover because of a 
high perceived complication rate associated with the 
latter procedure. It is claimed that these complications 
include a high perioperative mortalit~ groin sepsis 
and graft infection, false aneurysm formation and 
poor long term patency) These complications may 
lead to graft failure with return of symptoms and 
possibly limb loss secondary to graft infection. In 
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addition further arterial surgery may be required to 
bypass progressive disease in the inflow and outflow 
arteries of the crossover graft. 
Since 1969, at the Royal Adelaide Hospital, we have 
managed patients with disabling claudication and 
unilateral iliac artery disease by femorofemoral cross- 
over graft rather than aortofemoral or iliofemoral 
bypass. We believe that the complications of femor- 
ofemoral crossover grafts are overstated and femor- 
ofemoral crossover is a safer procedure than aortic or 
iliac surgery. This paper reports our experience and 
the results achieved by this policy. In particular we 
have examined perioperative complications and long- 
term follow-up in terms of graft patenc~ limb loss, 
patient survival and complications uch as graft 
infection and false aneurysm formation. 
Patients and Methods 
Patients undergoing femorofemoral crossover grafts 
for disabling claudication during the 22 year period 
from 1971 to 1992 were identified from the Vascular 
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Studies Unit databases. The case notes were reviewed 
and details of operation, follow-up and complications 
were recorded. 
Statistical analysis 
Success, failure and complications were analysed 
according to the guidelines of the Society of Vascular 
Surgery (SVS) and the International Society for Cardi- 
ovascular Surgery (ISCVS). 2 Primary graft patency 
was defined as uninterrupted graft patency and 
secondary patency as procedures performed on the 
graft or anastomoses to maintain or restore patency. 
Patency was computed using the Kaplan-Meier 
method of life table analysis. 3 Patients who died or 
were lost to follow-up were censored at their last 
follow-up visit. Discrete variables were analysed 
using the Chi-squared test and p-values of less than 
0.05 were considered significant. 
Results 
During the 22 year period from 1971 to 1992, 427 
patients underwent a femorofemoral crossover graft at 
the Royal Adelaide Hospital. Of these, 211 procedures 
were performed for disabling claudication and form 
the basis of this study. There were 175 males (83%) and 
36 females (17%) with a group mean age of 68 years 
(range 36-99 years). Fifteen patients (7%) were dia- 
betic. One hundred and seventy-three patients (82%) 
had stenosis or occlusion of the native iliac artery and 
38 patients (18%) had occlusion of a previous vascular 
procedure (bypass, endarterectomy or angioplasty) 
(Table 1). The inflow to the crossover graft was the 
native femoral artery in 174 patients (82%) and a 
patent graft in 37 patients (18%). Details of the inflow 
and outflow arteries are shown in Table 2. The 
cumulative graft patencies, limb and patient survival 
are shown in Fig. 1. There were no deaths in the first 
Table 1. Details of failed iliac artery vascular procedures (arterial 
bypass, endarterectomy, angioplasty) performed prior to 
femorofemoral crossover graft (n=38). 
Ocduded limb of aortobifemoral bypass 22 
Failed iliac balloon angioplasty 4 
Ocduded unilateral ipsilateral iliofemoral bypass 4 
Occluded iliac endarterectomy 4 
Ocduded limb of aortob'filiac bypass 2 
Ocduded femorofemoral crossover graft* 2 
*Performed in other vascular centre. 
Table 2. Details of inflow and outflow to femorofemoral crossover 
grafts (n=211). 
Inflow 
Common femoral artery 170 
Superficial femoral artery 4 
Patent graft:* 
Aortobifemoral graft (recipient limb occluded) 28 
Ipsilateral iliofemoral graft 8 
Proximal end of femoropopliteal graft 1 
Outflow 
Common femoral artery 164 
Superficial femoral artery 9 
Profunda femoris artery 34 
Proximal end of femoropopliteal graft 1 
*Performed at a mean of 36 months prior to femorofemoral crossover 
graft. 
Table 3. Graft patenc3~ limb survival and patient survival rates. 
1 year 5 years 10 years 13 years 
(%) (%) (%) (%) 
Primary patency 96 72 64 59 
Secondary patency 98 89 87 87 
Limb survival 99 97 97 97 
Patient survival 98 80 64 58 
Table 4. Indications for removal of femorofemoral grafts (n=12). 
PTFE (n=145) Dacron (n=66) 
False aneurysm formation 1 4 
Graft infection 1 3 
Infected false aneurysm 2 1 
Total 4 (2.7%) 8 (12.1%) 
p<0.001 PTFE vs. Dacron graft removal, df=l, Chi-square. 
Table 5. Details of subsequent inflow procedures following 
femorofemoral crossover graft (n=41). 
Aortofemoral bypass (mxilateral) 
Aorta to crossover graft bypass (unilateral) 
Aortobifemoral bypass 
Iliofemoral bypass (unilateral) 
Iliac to crossover graft bypass (unilateral) 
Axillofemoral bypass 
Donor iliac endarterectomy 
Donor iliac artery balloon angioplasty 
Aortopopliteal bypass (unilateral) 
Mean time 27 months (range 1-78) following femorofemoral 
crossover graft. 
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Table 6. Indications for inflow procedure following femoro -  
femora l  c rossover  gra f t  (n=41). 
Occluded femorofemoral crossover 
Infection or false aneurysm 
Donor steal 
Infection of aortic graft proximal to crossover 






Tab le  7. Deta i l s  o f  out f low procedures  (n=37)  in  32  pat ients .  
Donor Recipient 
limb limb Total 
Crossover or femoral to distal bypass 12 18 30 
Crossover to prohmda femoris bypass 1 1 2 
Profundaplasty 0 3 3 
Aortopopliteal bypass 1 0 1 
SFA angioplasty 0 1 1 
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Fig. 2. Cumulative primary patencies for PTFE vs. Dacron femorofemoral crossover grafts. The standard error is less than 10% at all time 
points. 
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30 days following operation and the primary graft 
patenc)~ secondary graft patenc)~ limb survival and 
patient survival rates at I year were 96% 98%, 99% and 
98% respectively (Table 3). One hundred and forty- 
five grafts (69%) were PTFE (W. L. Gore, Flagstaff, AZ, 
U.S.A.) and 66 (31%) were Dacron. The cumulative 
primary patencies for PTFE versus Dacron grafts are 
shown in Fig. 2. Seventy five patients (36%) had an 
outflow procedure performed at the same time as the 
femorofemoral crossover graft (32 Miller vein cuffs, 20 
vein patches, 19 profundaplasties and 3 femoral 
endarterectomies). Twelve grafts (4 PTFE, 8 Dacron) 
have been removed because of graft infection or false 
aneurysm formation; there were significantly fewer of 
these complications in the PTFE group (p<0.001, 
df = 1, Chi-square) (Table 4). Five patients (2%) have 
subsequently undergone a major lower limb amputa- 
tion at a mean time of 67 months postoperatively. 
These comprised two amputations of the inflow limb 
(1 patent crossover, 1 occluded crossover) and three 
amputations of the outflow limb (1 patent crossover, 2 
occluded crossovers). Forty-one patients (19%) have 
subsequently undergone an inflow procedure (Table 5) 
and the indication for these are shown in Table 6. 
Thirty-seven outflow procedures were performed in 
32 patients (Table 7). Six patients underwent throm- 
bectomy of an occluded crossover graft and 27 had a 
second crossover graft inserted. Of these, six were at 
the same site, five had a new inflow site, 10 had a new 
outflow site and six had both a new inflow and 
outflow site. 
Angiograms were available for review in 162 
patients (77%). Of these 87 patients had a patent 
recipient superficial femoral artery and 75 had an 
occluded recipient superficial femoral artery. There 
were no significant differences in cumulative primary 
graft patency between these two groups (p = 0.103, 
df = 1, log rank). 
Discussion 
The first femorofemoral crossover graft was per- 
formed at the Royal Adelaide Hospital in 1969, and 
since then, haemodynamically significant unilateral 
iliac artery stenosis and occlusion has been managed 
by femorofemoral grafts. Our experience does not 
support he often quoted objections to the procedure 
namely a high incidence of groin sepsis, a higher 
perioperative mortality and poor long term patency. ~'4 
Consequently we do not reserve the operation for 
patients with critical leg ischaemia or complications 
(infection or false aneurysm formation) associated 
with previous vascular surgery but use it as a primary 
treatment option in patients with disabling claudica- 
tion caused by unilateral iliac artery disease. Good 
graft patency rates together with a low complication 
rate have been reported by others -9 and make it a 
preferred alternative to aortofemoral bypass, which 
can have a high mortality in patients with cardior- 
espiratory disease. In this series, there have been no 
deaths in the perioperative period (30 day mortality) 
in 211 patients. In the early years of this series, Dacron 
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PTFE has been used (145 patients). Although there has 
been no difference in patency between the two grafts, 
graft removal for complications such as false aneu- 
rysm formation or infection was necessary in only 
four (2.7%) of the PTFE grafts compared to eight 
(12.1%) of the Dacron grafts (p< 0.001, Chi-square). 
However these results must be treated with caution as 
this is a retrospective study and patients were not 
randomised to receiving a Dacron or PTFE graft. 
In patients who require a graft directly onto the 
profunda femoris arter)~ we expose the profunda as 
far distally as required until a disease free, soft artery 
is found. In addition we use a vein collar on the 
profunda rtery. Although we do not have any data to 
support this technique, it is interesting to note that 
there were no significant differences in primary graft 
patency in patients with a patent vs. occluded recipi- 
ent superficial femoral artery. However angiograms 
were only available for 162 patients (77%). 
The long term follow-up in this series (mean 3.5 
years, range 0.5-13 years) has allowed an assessment 
for the subsequent eed for an inflow procedure. Out 
of 41 subsequent inflow procedures, 20 were per- 
formed for occlusion Of the crossover graft and 13 
were for donor steal in the presence of a patent 
crossover graft (Table 6). The cumulative need for an 
inflow procedure was 5% per year (mean 27 months 
after crossover graft, range 1-78 months). The primary 
patency at 5 years (72%) was increased by secondary 
procedures (thrombectomy and local revision) to 89%, 
which compares favourably with published reports of 
patency for aortofemoral grafts. 
In summar3~ a policy of performing femorofemoral 
crossover grafts in patients with disabling claudica- 
tion caused by unilateral i iac artery disease produces 
good long term patency and is associated with a low 
complication rates. It should be considered as an 
alternative to aortofemoral grafting in these patients. 
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